Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

Patrick Schöffski(KU Leuven), Hendrik Van Poppel(Universitair Ziekenhuis Leuven), Pascal Wolter(KU Leuven), Herlinde Dumez, Ann Hoeben(Maastricht University Medical Centre), Hans Prenen(Antwerp University Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Tania Roskams(KU Leuven), Steven Joniau
Annals of Oncology
January 17, 2006
10.1093/annonc/mdj133
Cited by 90

Related Papers

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k